Mutants of the factor VII-activating protease and detection methods using specific antibodies

US6831167B2 · kind B2 · utility

Assignee

• Aventis Behring GmbH · DE

Inventors

• Juergen Roemisch · Marburg, DE
• Hans-Arnold Stoehr · Wetter, DE
• Annette Feussner · Marburg, DE
• Wiegand Lang · Cölbe, DE
• Thomas Weimer · Gladenbach, DE
• Margret Becker · Marburg, DE
• Claudia Nerlich · Marburg, DE
• Gudrun Muth-Naumann · Wetter, DE

Key dates

• Filing date: Jul 26, 2001
• Grant date: Dec 14, 2004
• Expiry date: Aug 23, 2021

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/96463
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Mutants of the DNA sequence coding for the protease (FSAP) which activates blood clotting factor VII and single-chain plasminogen activators, the mutants comprising a G/C base exchange at nucleotide position 1177 and/or a G/A base exchange at nucleotide position 1601, are described. The corresponding protease has a Glu/Gln exchange at amino acid position 393 and/or a Gly/Glu exchange at amino acid position 534. Diagnostic methods which are used for detecting FSAP in body fluids or tissue cells and also for identifying patients with genetic heterozygous or homozygous FSAP expression are also described. In addition, antibodies against FSAP and its mutants are disclosed and diagnostic methods which can be used to detect antibodies against FSAP and its mutants are specified.